Drug Combination Details
| General Information of the Combination (ID: C08946) | |||||
|---|---|---|---|---|---|
| Name | Thymoquinone NP Info | + | Bortezomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | COL11A2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MKI67 | Molecule Info | |||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | ||
| NCI-H929 | CVCL_1600 | Plasma cell myeloma | Homo sapiens | |||
| KMS-11 | CVCL_2989 | Plasma cell myeloma | Homo sapiens | |||
| RPMI-8226 | CVCL_0014 | Plasma cell myeloma | Homo sapiens | |||
| In-vivo Model | Five-week-old athymic nu/nu male Balb/c mice were implanted subcutaneously in the right flank with U266 cells (2 * 106 cells/100 uL of PBS/Matrigel). | |||||
| Experimental
Result(s) |
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-KappaB regulated gene products in multiple myeloma xenograft mouse model. | |||||
